Antileukotrienes in asthma - critical view

This article discusses the role of cysteinyl leukotrienes in asthma and addresses the problem of the use of leukotriene receptor antagonists (LTRA) in the treatment of asthma. The author points out that these drugs are inferior to inhaled corticosteroids and long acting beta agonists and should be u...

Full description

Saved in:
Bibliographic Details
Published inPneumonologia i alergologia polska Vol. 78; no. 1; pp. 60 - 67
Main Author Droszcz, Wacław
Format Journal Article
LanguagePolish
Published Poland 2010
Subjects
Acetates - adverse effects
Adrenal Cortex Hormones - therapeutic use
Adult
Adverse Drug Reaction Reporting Systems
Anti-Asthmatic Agents - adverse effects
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy
Asthma - prevention & control
Bronchodilator Agents - therapeutic use
Child
Churg-Strauss Syndrome - chemically induced
Churg-Strauss Syndrome - diagnosis
Drug Interactions
Humans
Leukotriene Antagonists - adverse effects
Leukotriene Antagonists - therapeutic use
Leukotrienes - metabolism
Practice Guidelines as Topic
Risk Assessment
Online AccessGet full text

Cover

More Information
Summary:This article discusses the role of cysteinyl leukotrienes in asthma and addresses the problem of the use of leukotriene receptor antagonists (LTRA) in the treatment of asthma. The author points out that these drugs are inferior to inhaled corticosteroids and long acting beta agonists and should be used as "add on" drugs being a third choice in the management of asthma. Lack of response to LTRA has a genetic background. Side effects of LTRA therapy is discussed, particularly Churg-Strauss syndrome. According to the recent literature, LTRA monotherapy should not be applied. In general, the author suggests that there is a risk of LTRA overtreatment particularly in children.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:0867-7077